Coinbase founder Armstrong raises $435 million for longevity startup

Brian Armstrong, founder of crypto exchange Coinbase, sees his longevity startup NewLimit close a substantial funding round. The company raises no less than $435 million in Series C, showing that investments in anti-ageing technology are very much in motion. The round is led by Founders Fund, while new investors such as Thrive Capital, Greenoaks and Quiet Capital join. Existing backers Kleiner Perkins and Eli Lilly Ventures also participate again.

NewLimit focuses on age reprogramming

NewLimit is working on innovative technologies to counter the ageing process. The company announced that it plans to bring its first drug for age reprogramming into human trials next year. This marks an important moment for the biotech sector, where Armstrong is now actively involved as an entrepreneur outside the crypto world.

The funding round underscores growing confidence in NewLimit’s approach. With this fresh capital injection, the company can take the necessary steps to accelerate its research and development programmes.

Armstrong diversifies beyond Coinbase

The Coinbase co-founder increasingly shows himself to be a versatile entrepreneur. Besides his role at the cryptocurrency exchange, which recently announced partnerships, Armstrong is now focusing on longevity science. This initiative indicates that leading crypto figures are expanding their investment portfolios into other industries.

NewLimit’s ambition aligns with a broader trend in the technology sector, where increasing attention is being paid to extending and improving human life. With this $435 million round, it is clear that Armstrong’s vision on longevity enjoys considerable support from leading venture capital firms.